Influence of corticosteroid therapy on the serum antibody response to influenza vaccine in elderly patients with chronic pulmonary diseases

Authors

  • Sumito Inoue Departments of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan
  • Yoko Shibata Departments of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan
  • Noriaki Takabatake Departments of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan
  • Akira Igarashi Departments of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan
  • Shuichi Abe Departments of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan
  • Isao Kubota Departments of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan

Keywords:

corticosteroid, influenza vaccine, chronic pulmonary disease

Abstract

Annual influenza vaccination is strongly recommended for patients with chronic pulmonary diseases, such as bronchial asthma, chronic obstructive pulmonary disease (COPD), and interstitial pulmonary diseases. However, many of these patients regularly receive systemic and/or inhaled corticosteroid therapy, and the impact of corticosteroid therapy on influenza vaccine efficacy and safety is unclear. Patients with chronic pulmonary diseases were enrolled in the study and divided into three groups based on their maintenance therapy: (A) without corticosteroid therapy (17 males, three females; mean age, 72.3 ± 7.9), (B) oral corticosteroid therapy (four males, seven females; mean age, 66.1 ± 10.6), and (C) inhaled corticosteroid therapy (eight males, nine females; mean age, 62.4 ± 16.0). All patients received influenza vaccine, and serum hemagglutination inhibition (HI) antibodies against influenza strains A/H1N1, A/H3N2, and B were measured at baseline (before vaccination) and 4-6 weeks after vaccination. Sufficient antibody titers or significant increases were observed after vaccination compared with titers before vaccination in all three groups. No systemic reactions were reported. Long-term oral/inhaled corticosteroid therapy was not associated with vaccination side effects and did not affect the immune response to the influenza vaccine.

Downloads

Published

2013-08-29

How to Cite

Inoue, S., Shibata, Y., Takabatake, N., Igarashi, A., Abe, S., & Kubota, I. (2013). Influence of corticosteroid therapy on the serum antibody response to influenza vaccine in elderly patients with chronic pulmonary diseases. EXCLI Journal, 12, 760–765. Retrieved from https://www.excli.de/index.php/excli/article/view/1190

Issue

Vol. 12 (2013)

Section

Original articles

License

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).

Most read articles by the same author(s)